The Scientific Team at Frontera Therapeutics is responsible for the research and development of innovative AAV gene therapies. They focus on upstream process development, scientific advisory roles, and ensuring the production of high-quality, scalable, and cost-effective rAAV therapies to meet global healthcare needs.
Amy Jiang
Principal Associate Scientist
Fraser Wright
Scientific Advisor
George Church
Scientific Advisor
Glenn Pierce
Scientific Advisor
Hongbin Xu
Principal Scientist
Jean Bennett
Scientific Advisor
Mark Kay
Scientific Advisor
Mullu Tessema
Principal Associate Scientist
Robert Kotin
Scientific Advisor
Xandra Breakefield
Scientific Advisor
View all